April 22 (Reuters) - Regenxbio Inc RGNX.O :
* REGENXBIO ANNOUNCES ADDITIONAL POSITIVE LONG-TERM AND INTERIM PHASE I/IIA TRIAL UPDATE FOR RGX-314 FOR THE TREATMENT OF WET AMD
* REGENXBIO INC - RGX-314 CONTINUES TO BE WELL-TOLERATED AT ALL DOSE LEVELS
* REGENXBIO INC - ON TRACK TO PROVIDE ONE-YEAR DATA FROM COHORTS 4 & 5 IN MID-2020 AND INITIATE RGX-314 SUBRETINAL DELIVERY PIVOTAL PROGRAM IN 2H 2020
* REGENXBIO INC - LONG-TERM, DURABLE TREATMENT EFFECT DEMONSTRATED OVER TWO YEARS IN COHORT 3 IN WET AMD TRIAL
* REGENXBIO INC - IN WET AMD TRIAL, 50% OF PATIENTS REMAIN ANTI-VEGF INJECTION-FREE OVER TWO YEARS
* REGENXBIO INC - IN WET AMD TRIAL, 67% OF PATIENTS ARE ANTI-VEGF INJECTION-FREE FROM NINE MONTHS TO TWO YEARS
Source text for Eikon: Further company coverage: